Treatment Patterns, Clinical Events, and Costs of Care for Patients With Triple Negative Metastatic Breast Cancer: A Retrospective US Claims Database Study
Our study focused on patients with mTNBC with the greatest unmet need, namely those ineligible for immunotherapy. In patients with mTNBC, most of whom received chemotherapy as standard of care, CEIs presented both a clinical and economic burden, highlighting the need for newer treatments that balance total costs of care with adverse events and clinical benefit.
Authors
- Tiffany A. Traina (ORCID: https://orcid.org/0000-0003-3597-0050)
- Jenny Y. M. Tse (ORCID: https://orcid.org/0000-0002-0035-2079)
- Manali Bhave (ORCID: https://orcid.org/0000-0003-4020-5871)
- Nazneen Fatima Shaikh (ORCID: https://orcid.org/0000-0002-4184-1610)
- Dajun Tian (ORCID: https://orcid.org/0000-0001-8147-8564)
- Aimee M. Near (ORCID: https://orcid.org/0000-0001-9423-8244)
- Simon M. Collin (ORCID: https://orcid.org/0000-0002-1239-1681)
Institutions
- AstraZeneca (United Kingdom) (GB)
- Memorial Sloan Kettering Cancer Center (US)
- Emory University (US)
- Genesis Health System (US)
- IQVIA (United Kingdom) (GB)
- IQVIA (United States) (US)
- AstraZeneca (Singapore) (SG)
- IQ Solutions (US)
Publication Details
- Journal
- Journal of health economics and outcomes research
- Published
- 2025-11-06
- DOI
- https://doi.org/10.36469/001c.144499
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Gilead Sciences
- Veracyte
- Genentech
- Daiichi Sankyo Europe